Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.

  • Read more about Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.

Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.

  • Read more about Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.

Lifespan care in SCD: Whom to transition, the patients or the health care system?

  • Read more about Lifespan care in SCD: Whom to transition, the patients or the health care system?

Transcranial doppler re-screening of subjects who participated in STOP and STOP II.

  • Read more about Transcranial doppler re-screening of subjects who participated in STOP and STOP II.

Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis.

  • Read more about Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis.

Pain over time and its effects on life in thalassemia.

  • Read more about Pain over time and its effects on life in thalassemia.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

  • Read more about Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Pregnancy outcomes in women with thalassemia in North America and the United Kingdom.

  • Read more about Pregnancy outcomes in women with thalassemia in North America and the United Kingdom.

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.

  • Read more about Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.

Exercise performance in thalassemia major: correlation with cardiac iron burden.

  • Read more about Exercise performance in thalassemia major: correlation with cardiac iron burden.

Pagination

  • Previous page ‹‹
  • Page 3
  • Next page ››
Subscribe to American journal of hematology

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List